Venus Concept (VERO) Shares Surge 300% Following 13D/A Filing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: NASDAQ.COM
- Stock Surge: Venus Concept Inc. (VERO) shares soared 300% in pre-market trading on Friday, currently priced at $7.25, reflecting a 405% increase from the previous trading day, indicating strong market confidence in its future potential.
- Shareholder Holdings: According to the amended 13D/A filing dated January 15, 2026, Madryn Asset Management holds 18,763,125 shares, representing a 91% stake in the company, showcasing its significant influence over corporate governance.
- Cost Reduction Proposal: On January 13, 2026, Madryn discussed with the board its desire to reduce operational costs, including potential delisting and deregistration of the company's common stock, which could impact the company's strategic direction moving forward.
- Global Market Presence: Venus Concept is a global medical aesthetics technology company specializing in energy-based devices and robotic hair restoration systems, with products marketed in over 60 countries, covering body contouring and skin tightening, demonstrating its extensive market reach.
Analyst Views on VERO
About VERO
Venus Concept Inc. is a global medical technology company. The Company develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services and reaches over 60 countries and nine direct markets. The Company’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa Pro, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Its treatments for hair loss are divided into non-surgical options and surgical procedures. Its hair restoration systems include NeoGraft and the ARTAS iX Robotic Hair Restoration system. Its systems are designed on flexible platforms that enable it to expand beyond the aesthetic industry’s traditional markets of dermatology and plastic surgery, and into non-traditional markets, including family medicine and general practitioners and aesthetic medical spas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
